Fragment-based approaches and computer-aided drug discovery.

[1]  John P. Overington,et al.  Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. , 2010, Drug discovery today.

[2]  Jennifer Venhorst,et al.  Design of a high fragment efficiency library by molecular graph theory. , 2010, ACS medicinal chemistry letters.

[3]  J. Piette,et al.  NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. , 2010, Bioorganic & medicinal chemistry letters.

[4]  Zhihai Liu,et al.  Evaluation of the performance of four molecular docking programs on a diverse set of protein‐ligand complexes , 2010, J. Comput. Chem..

[5]  Chenglong Li,et al.  Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein , 2010, J. Comput. Chem..

[6]  G. F. Ruda,et al.  Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase , 2010, Bioorganic & medicinal chemistry.

[7]  X. Barril,et al.  Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.

[8]  Oleg V Stroganov,et al.  Improving performance of docking-based virtual screening by structural filtration , 2010, Journal of molecular modeling.

[9]  Gerhard Klebe,et al.  Fragment‐Based Lead Discovery: Screening and Optimizing Fragments for Thermolysin Inhibition , 2010, ChemMedChem.

[10]  Jie Shen,et al.  Accuracy Assessment of Protein-Based Docking Programs against RNA Targets , 2010, J. Chem. Inf. Model..

[11]  Kengo Kinoshita,et al.  Ligand-binding site prediction of proteins based on known fragment–fragment interactions , 2010, Bioinform..

[12]  Robert Kiss,et al.  Virtual Fragment Docking by Glide: a Validation Study on 190 Protein-Fragment Complexes , 2010, J. Chem. Inf. Model..

[13]  Claudio Luchinat,et al.  Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.

[14]  M. Jacobson,et al.  Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.

[15]  Roy J. Vaz,et al.  Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. , 2010, Bioorganic & medicinal chemistry letters.

[16]  Miles Congreve,et al.  The impact of GPCR structures on pharmacology and structure‐based drug design , 2010, British journal of pharmacology.

[17]  Aurélien Grosdidier,et al.  Rational design of indoleamine 2,3-dioxygenase inhibitors. , 2010, Journal of medicinal chemistry.

[18]  Amedeo Caflisch,et al.  Library screening by fragment‐based docking , 2009, Journal of molecular recognition : JMR.

[19]  Woody Sherman,et al.  Computational approaches for fragment-based and de novo design. , 2010, Current topics in medicinal chemistry.

[20]  Dima Kozakov,et al.  Binding hot spots and amantadine orientation in the influenza a virus M2 proton channel. , 2009, Biophysical journal.

[21]  Matthew Clark,et al.  Fragment-Based Prediction of the Clinical Occurrence of Long QT Syndrome and Torsade de Pointes , 2009, J. Chem. Inf. Model..

[22]  Masaya Orita,et al.  Advances in fragment-based drug discovery platforms , 2009, Expert opinion on drug discovery.

[23]  Ian A. Watson,et al.  Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. , 2009, Journal of medicinal chemistry.

[24]  Alexander D. MacKerell,et al.  Computational Fragment-Based Binding Site Identification by Ligand Competitive Saturation , 2009, PLoS Comput. Biol..

[25]  Wendy A. Warr,et al.  Fragment-based drug discovery , 2009, J. Comput. Aided Mol. Des..

[26]  Mark Whittaker,et al.  The multiple roles of computational chemistry in fragment-based drug design , 2009, J. Comput. Aided Mol. Des..

[27]  Dima Kozakov,et al.  Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase , 2009, J. Comput. Aided Mol. Des..

[28]  Collin M. Stultz,et al.  The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design , 2009, J. Comput. Aided Mol. Des..

[29]  Lorenz C. Blum,et al.  970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.

[30]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[31]  Matthew Paul Gleeson,et al.  QM/MM As a Tool in Fragment Based Drug Discovery. A Cross-Docking, Rescoring Study of Kinase Inhibitors , 2009, J. Chem. Inf. Model..

[32]  Woody Sherman,et al.  Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation , 2009, J. Comput. Aided Mol. Des..

[33]  Denise G. Teotico,et al.  Docking for fragment inhibitors of AmpC β-lactamase , 2009, Proceedings of the National Academy of Sciences.

[34]  L. Mario Amzel,et al.  Impact of linker strain and flexibility in the design of a fragment-based inhibitor , 2009, Nature chemical biology.

[35]  Haruki Nakamura,et al.  In Silico Fragment Screening by Replica Generation (FSRG) Method for Fragment-Based Drug Design , 2009, J. Chem. Inf. Model..

[36]  Somesh D. Sharma,et al.  Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.

[37]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[38]  Kazuki Ohno,et al.  Two 'Golden Ratio' indices in fragment-based drug discovery. , 2009, Drug discovery today.

[39]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[40]  Thomas A. Halgren,et al.  Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..

[41]  Luca Sartori,et al.  Identification and Selection of "Privileged Fragments" Suitable for Primary Screening , 2008, J. Chem. Inf. Model..

[42]  Matthias Rarey,et al.  On the Art of Compiling and Using 'Drug‐Like' Chemical Fragment Spaces , 2008, ChemMedChem.

[43]  Glen E Kellogg,et al.  Novel inhibitors of anthrax edema factor. , 2008, Bioorganic & medicinal chemistry.

[44]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[45]  Chris G. Kruse,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[46]  D. Case,et al.  Rescoring docking hit lists for model cavity sites: predictions and experimental testing. , 2008, Journal of molecular biology.

[47]  Andreas Bender,et al.  "Virtual fragment linking": an approach to identify potent binders from low affinity fragment hits. , 2008, Journal of medicinal chemistry.

[48]  Christopher R. Corbeil,et al.  Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.

[49]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[50]  D. Pereira,et al.  Origin and evolution of high throughput screening , 2007, British journal of pharmacology.

[51]  Brett A Tounge,et al.  The role of molecular size in ligand efficiency. , 2007, Bioorganic & medicinal chemistry letters.

[52]  Olivier Roche,et al.  A new class of histamine H3 receptor antagonists derived from ligand based design. , 2007, Bioorganic & medicinal chemistry letters.

[53]  Aniko Simon,et al.  eHiTS: a new fast, exhaustive flexible ligand docking system. , 2007, Journal of molecular graphics & modelling.

[54]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.

[55]  Matthias Rarey,et al.  Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations , 2007, J. Chem. Inf. Model..

[56]  Harald Mauser,et al.  Chemical Fragment Spaces for de novo Design , 2007, J. Chem. Inf. Model..

[57]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[58]  D. Erlanson.  Fragment-based lead discovery: a chemical update. , 2006, Current opinion in biotechnology.

[59]  Peter Willett,et al.  Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.

[60]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[61]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[62]  D. V. Von Hoff,et al.  Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.

[63]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[64]  Christian Rummey,et al.  In silico fragment-based discovery of DPP-IV S1 pocket binders. , 2006, Bioorganic & medicinal chemistry letters.

[65]  Peter Willett,et al.  Knowledge-Based Interaction Fingerprint Scoring: A Simple Method for Improving the Effectiveness of Fast Scoring Functions , 2006, J. Chem. Inf. Model..

[66]  Thomas Bäck,et al.  Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..

[67]  Timo Heikkilae,et al.  The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. , 2006, Bioorganic & medicinal chemistry letters.

[68]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.

[69]  Edgar Jacoby,et al.  Library design for fragment based screening. , 2005, Current topics in medicinal chemistry.

[70]  Didier Rognan,et al.  Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor. , 2005, Journal of medicinal chemistry.

[71]  P. Hajduk,et al.  Druggability indices for protein targets derived from NMR-based screening data. , 2005, Journal of medicinal chemistry.

[72]  O. El-Kabbani,et al.  Structure-based discovery of human L-xylulose reductase inhibitors from database screening and molecular docking. , 2005, Bioorganic & medicinal chemistry.

[73]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[74]  G. S. Gill,et al.  Molecular surface point environments for virtual screening and the elucidation of binding patterns (MOLPRINT) , 2004, 2004 IEEE International Conference on Systems, Man and Cybernetics (IEEE Cat. No.04CH37583).

[75]  Brian Dymock,et al.  Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets , 2004, J. Chem. Inf. Model..

[76]  G. Bemis,et al.  A minimalist approach to fragment‐based ligand design using common rings and linkers: Application to kinase inhibitors , 2004, Proteins.

[77]  Ricardo L. Mancera,et al.  Expanded Interaction Fingerprint Method for Analyzing Ligand Binding Modes in Docking and Structure-Based Drug Design , 2004, J. Chem. Inf. Model..

[78]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[79]  Gisbert Schneider,et al.  Identification of novel cannabinoid receptor ligands via evolutionary de novo design and rapid parallel synthesis , 2004 .

[80]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[81]  G. Bemis,et al.  BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease. , 2004, Journal of medicinal chemistry.

[82]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[83]  Paul Watson,et al.  Virtual Screening Using Protein-Ligand Docking: Avoiding Artificial Enrichment , 2004, J. Chem. Inf. Model..

[84]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[85]  M. Congreve,et al.  A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.

[86]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[87]  H. M. Vinkers,et al.  SYNOPSIS: SYNthesize and OPtimize System in Silico. , 2003, Journal of medicinal chemistry.

[88]  Neera Borkakoti,et al.  Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. , 2003, Bioorganic & medicinal chemistry letters.

[89]  Min Zhang,et al.  Structure-based de novo design, synthesis, and biological evaluation of non-azole inhibitors specific for lanosterol 14alpha-demethylase of fungi. , 2003, Journal of medicinal chemistry.

[90]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[91]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[92]  Sandor Vajda,et al.  Computational mapping identifies the binding sites of organic solvents on proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[93]  G. Whitesides,et al.  Combinatorial computational method gives new picomolar ligands for a known enzyme , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[94]  K. Fukasawa,et al.  Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. , 2001, Journal of medicinal chemistry.

[95]  Shingo Makino,et al.  Discovery of a novel serine protease inhibitor utilizing a structure-based and experimental selection of fragments technique , 2001, J. Comput. Aided Mol. Des..

[96]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[97]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[98]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[99]  D. Kostrewa,et al.  Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. , 2000, Journal of medicinal chemistry.

[100]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[101]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Robin Taylor,et al.  SuperStar: a knowledge-based approach for identifying interaction sites in proteins. , 1999, Journal of molecular biology.

[103]  T Lengauer,et al.  The particle concept: placing discrete water molecules during protein‐ligand docking predictions , 1999, Proteins.

[104]  Hans-Joachim Böhm,et al.  Combinatorial docking and combinatorial chemistry: Design of potent non-peptide thrombin inhibitors , 1999, J. Comput. Aided Mol. Des..

[105]  I D Kuntz,et al.  CombiDOCK: Structure-based combinatorial docking and library design , 1998, Journal of computer-aided molecular design.

[106]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[107]  Transformation of Peptides into Non-Peptides. Synthesis of Computer-Generated Enzyme Inhibitors , 1997, CHIMIA.

[108]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[109]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[110]  D. Ringe,et al.  Locating and characterizing binding sites on proteins , 1996, Nature Biotechnology.

[111]  J. C. Dyason,et al.  A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs. , 1996, Journal of medicinal chemistry.

[112]  C. Kissinger,et al.  Design, synthesis and X-ray crystallographic studies of novel FKBP-12 ligands , 1995 .

[113]  D. Rognan,et al.  Rational design of nonnatural peptides as high-affinity ligands for the HLA-B*2705 human leukocyte antigen. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[114]  Gerhard Klebe,et al.  A fast and efficient method to generate biologically relevant conformations , 1994, J. Comput. Aided Mol. Des..

[115]  M Karplus,et al.  HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding site , 1994, Proteins.

[116]  Hans-Joachim Böhm,et al.  The computer program LUDI: A new method for the de novo design of enzyme inhibitors , 1992, J. Comput. Aided Mol. Des..

[117]  M. Karplus,et al.  Functionality maps of binding sites: A multiple copy simultaneous search method , 1991, Proteins.

[118]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.

[119]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[120]  W. Jencks,et al.  On the attribution and additivity of binding energies. , 1981, Proceedings of the National Academy of Sciences of the United States of America.